added and the solution was purged for another 20 min under
bubbling Ar. Donor segment 8 or 10 (2.5 equiv.) was dissolved
in THF (0.04 M), the solution was purged for 30 min under
bubbling Ar, and then injected via syringe pump into the stirred
polyyne solution over 8 h at 55 ◦C under an Ar atmosphere. The
reaction was stirred until complete by TLC. The mixture was then
concentrated, rediluted with hexanes–CH2Cl2 (4 : 1), and filtered
through a pad of silica gel. The solvent was removed in vacuo, and
the crude material was purified by column chromatography.
(72 mg, 0.148 mmol) at rt for 16 h using general alkyne coupling
procedure B. The crude material was chromatographed on silica
gel (4 : 1 hexanes–CH2Cl2) to give 13 (153 mg, 87%) as a red
oil. mmax (KBr)/cm−1 2958, 2937, 2860, 2150, 1652, 1591, 1540,
1506, 1472, 1457, 1338, 1277. dH (300 MHz; CDCl3; Me4Si) 7.82
(2 H, s), 7.72 (2 H, s), 7.20 (2 H, s), 3.12 (8 H, t, J 6.9 Hz),
1.53 (8 H, quin, J 7.5), 1.29 (8 H, sext, J 7.5), 1.15 (42 H, s),
0.88 (12 H, t, J 7.2). dC (75 MHz; CDCl3; Me4Si) 144.25, 140.92,
137.61, 130.59, 128.52, 126.35, 125.21, 124.54, 116.94, 102.96,
96.13, 81.84, 81.51, 80.07, 78.98, 51.96, 29.71, 20.29, 18.98, 14.06,
11.54. m/z (APCI) 1187 (M+(279Br), 42%), 1189 (MH+(79Br81Br),
100), 1190 (MH+(13C281Br), 65).
DBA precursor 14. Segment 10 (106 mg, 0.192 mmol) was
cross-coupled to acceptor-functionalized arene 13 (106 mg, 0.089
mmol) at 55 ◦C using general alkyne coupling procedure C (10
h). The crude material was chromatographed on silica gel (4 :
1 hexanes–CH2Cl2) to give 14 (111 mg, 63%) as a dark red oil.
kmax (CH2Cl2)/nm 294 (log e/dm3 mol−1 cm−1, 4.97), 322 (4.98),
353 (4.94), 445 (4.59). mmax (NaCl)/cm−1 2953, 2932, 2891, 2856,
2218, 2147, 1595, 1536, 1505, 1487, 1466, 1428, 1337, 1274. dH
(300 MHz; CDCl3; Me4Si) 7.90 (2 H, s), 7.82 (2 H, s), 7.60 (2 H,
s), 7.22 (2 H, s), 7.10 (2 H, s), 3.13 (16 H, m), 1.52 (16 H, m),
1.29 (16 H, m), 1.16 (42 H, s), 1.14 (42 H, s), 0.88 (24 H, m). dC
(75 MHz; CDCl3; Me4Si) 145.32, 144.30, 140.91, 139.50, 138.01,
131.68, 131.62, 130.59, 128.79, 125.81, 125.55, 125.33, 124.11,
117.03, 113.25, 103.56, 102.98, 100.25, 99.87, 96.09, 82.71, 82.44,
81.63, 80.76, 80.29, 79.60, 78.86, 51.96, 51.76, 29.71, 20.26, 18.94,
14.02, 11.53.
Bis[18]DBA 7. Precursor 14 (65 mg, 0.033 mmol) was sub-
jected to general Pd-catalyzed cyclization procedure D (40 h).
The crude material was purified by filtration through a pad of
silica gel followed by concentration in vacuo and trituration with
hexanes to afford 7 (29 mg, 66%) as a dark orange powder. Mp:
160–180 ◦C (dec). kmax (CH2Cl2)/nm 403 (log e/dm3 mol−1 cm−1,
4.89), 479 (4.36). mmax (NaCl)/cm−1 2955, 2924, 2868, 2213, 1651,
1592, 1535, 1479, 1431, 1370. dH (300 MHz; CD2Cl2; Me4Si) 8.01
(2 H, s), 8.00 (2 H, s), 7.88 (2 H, s), 7.36 (2 H, s), 7.32 (2 H,
s), 3.20 (16 H, m), 1.55 (16 H, m), 1.29 (16 H, m), 0.91 (24 H,
m). dC (75 MHz; CDCl3; Me4Si) 145.09, 139.86, 139.75, 139.50,
137.46, 136.69, 131.72, 129.77, 129.41, 125.77, 125.25, 124.25,
124.06, 113.15, 113.03, 82.14, 81.92, 81.35, 81.27, 80.94, 80.78,
80.71, 80.19, 79.83, 79.41, 77.46, 77.41, 51.70, 29.71, 20.33, 14.05.
General Pd-catalyzed cyclization procedure D. Annulene pre-
cycle was dissolved in THF, Et2O and MeOH (2 : 1 : 0.01, 0.005
M) and Bu4NF (TBAF, 1.0 M soln in THF, 10 equiv.) was added.
The solution was stirred at room temperature until complete by
TLC (typically <1 h). The reaction mixture was then concentrated,
dissolved in Et2O, and washed with H2O (3 × 50 mL). The organic
phase was collected, dried over MgSO4, and filtered through a
pad of silica gel eluting with hexanes. The solvent was removed in
vacuo and the deprotected precycle was dissolved in THF (0.005
M). PdCl2(dppe) (0.1 equiv. per transformation), CuI (0.2 equiv.
per transformation), and I2 (0.25 equiv. per transformation) were
i
dissolved in Pr2NH–THF (3 : 2, ∼0.5 L per mmol precycle). To
this mixture, the deprotected precycle solution was injected via
syringe pump over 40 h at 65 ◦C. The reaction mixture was stirred
until complete by TLC, then concentrated, rediluted in hexanes–
CH2Cl2 (3 : 1) and filtered through a pad of silica gel. The solvent
was removed in vacuo and the product was triturated with hexanes.
DBA precursor 12. Segment 8 (306 mg, 0.605 mmol) was cross-
coupled to 1,2,4,5-tetraiodobenzene (78 mg, 0.134 mmol) at 55 ◦C
using general alkyne coupling procedure A (12 h). The crude
material was chromatographed on silica gel (4 : 1 hexanes–CH2Cl2)
to give 12 (227 mg, 94%) as a dark red oil. kmax (CH2Cl2)/nm 400
(log e/dm3 mol−1 cm−1, 4.73), 466 (4.81). Em. kmax/nm 551. Uf
12
0.18.
m
max
(NaCl)/cm−1 2959, 2935, 2856, 2191, 2155, 1589, 1530,
1479, 1365, 1223, 1113. dH (300 MHz; CDCl3; Me4Si) 7.51 (2 H,
s), 7.35 (4 H, d, J 9.0), 6.66 (4 H, d, J 2.7), 6.49 (4 H, dd, J 9.0,
2.7), 3.27 (16 H, t, J 7.5), 1.54 (16 H, quin, J 7.5), 1.34 (16 H,
sext, J 7.2), 1.18 (84 H, s), 0.96 (24 H, t, J 7.2). dC (75 MHz;
CDCl3; Me4Si) 148.30, 137.66, 134.58, 128.57, 125.49, 114.89,
111.72, 110.40, 105.84, 94.59, 85.37, 81.84, 78.87, 75.99, 50.78,
29.50, 20.48, 18.97, 14.16, 11.60. m/z (APCI) 1719 (M+ − TIPS +
THF, 66%), 1720 (M+(13C) − TIPS + THF, 100).
Bis[18]DBA 1. Precursor 12 (136 mg, 0.075 mmol) was sub-
jected to general Pd-catalyzed cyclization procedure D (40 h). The
crude material was purified by filtration through a pad of silica gel
followed by concentration in vacuo and trituration with hexanes
to afford 1 (72 mg, 82%) as a brick red powder. Once purified, the
product exhibited very poor solubility, thus precluding acquisition
of 13C-NMR data. Mp: 200–220 ◦C (dec). kmax (CH2Cl2)/nm 445
(log e/dm3 mol−1 cm−1, 4.96), 481 (4.98). Em. kmax/nm 551. Uf
0.34.12 mmax (KBr)/cm−1 2956, 2929, 2871, 2136, 1591, 1590, 1482,
1368, 1218, 1110. dH (300 MHz; CDCl3; Me4Si) 7.78 (2 H, s), 7.49
(4 H, d, J 8.7), 6.84 (4 H, s), 6.66 (4 H, d, J 11.4), 3.30 (16 H, t, J
6.9), 1.59 (16 H, m), 1.40 (16 H, sext, J 7.8), 0.99 (24 H, t, J 7.2).
dH (300 MHz; THF-d8; Me4Si) 7.84 (2 H, s), 7.50 (4 H, d, J 9.0),
6.92 (4 H, s), 6.80 (4 H, d, J 9.0), 3.39 (16 H, t, J 7.8), 1.63 (16 H,
m), 1.40 (16 H, sext, J 7.5), 0.99 (24 H, t, J 7.5).
Acknowledgements
We thank the National Science Foundation (CHE-0718242) for
financial support. E.L.S. acknowledges the NSF for an IGERT
fellowship (DGE-0549503). We thank the laboratory of Prof.
D. W. Johnson for use of the HypNMR program software.
Notes and references
1 (a) E. L. Spitler, C. A. Johnson and M. M. Haley, Chem. Rev., 2006,
106, 5344–5386; (b) J. A. Marsden, G. J. Palmer and M. M. Haley,
Eur. J. Org. Chem., 2003, 2355–2369.
2 (a) J. J. Pak, T. J. R. Weakley and M. M. Haley, J. Am. Chem. Soc.,
1999, 121, 8182–8192; (b) A. Sarkar, J. J. Pak, G. W. Rayfield and M. M.
Haley, J. Mater. Chem., 2001, 11, 2943–2945; (c) J. A. Marsden, J. J.
Miller, L. D. Shirtcliff and M. M. Haley, J. Am. Chem. Soc., 2005, 127,
2464–2476; (d) E. L. Spitler, S. P. McClintock and M. M. Haley, J. Org.
Chem., 2007, 72, 6692–6699; (e) S. Anand, O. Varnavski, J. A. Marsden,
Acceptor-functionalized arene 13. Segment 11 (198 mg, 0.359
mmol) was cross-coupled to 1,4-dibromo-2,5-diiodobenzene
This journal is
The Royal Society of Chemistry 2008
Org. Biomol. Chem., 2008, 6, 1569–1576 | 1575
©